Korkmaz, TanerSeber, SelçukKefeli, UmutSarı, EnesÖven, Bala BaşakYıldırım, EmreYaşar, NurgülBalvan, ÖzlemŞener, Nur DinçYüksel, SinemisGüven, Aslıhan MertPolat, ÖzgeYumuk, Perran FuldenGümüş, MahmutTurhal, Nazım Serdar2024-01-292024-01-292013-07Korkmaz, T. vd. (2013). ''Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: A retrospective analysis''. Clinical and Translational Oncology, 15(7), 535-540.1699-048Xhttps://link.springer.com/article/10.1007/s12094-012-0960-6https://hdl.handle.net/11452/39360Small cell lung cancer (SCLC) has a high relapse rate despite being very chemosensitive. The efficacy of second-line treatment is dismal. Our aim was to evaluate the outcome of second-line treatment. Methods: We retrospectively assessed data of 120 SCLC patients who failed first-line treatment and received second-line treatment at three medical oncology centers. Results: Median age of group was 58. 82 % had an ECOG PS of 0-1 at the time of relapse. 39 % were at limited stage (LS) at the time of diagnosis. Patients who progressed more than 3 months after first-line therapy were categorized as having platinum-sensitive disease (PSD) (64 %). The number of patients who received platin-based combination treatment was 33 (27 %). The median OS time starting from the initiation of second-line treatment was 7 months. Multivariate analysis identified PS (p = 0.006), extent of disease at diagnosis (0.014) and PSD (0.001) as the independent prognostic factors for survival. Subgroup analyses of the patients with PSD indicated platin rechallenge yields higher progression-free survival, overall survival and overall response rate. Conclusion: Patients with good ECOG PS,who have PSD or initially presenting with LS, have a good prognosis and in patients with PSD, platinum-based therapy would be more appropriate.eninfo:eu-repo/semantics/closedAccessOncologyPlatinum sensitive diseasePlatinum refracter diseaseSecond-line chemotherapySmall cell lung cancerPhase-IITopotecanChemotherapyEtoposideCisplatinProgressTherapyTrialCareAgedAntineoplastic agentsAntineoplastic combined chemotherapy protocolsCarboplatinFemaleHumansLung neoplasmsMaleMiddle agedRetrospective studiesSmall cell lung carcinomaSurvival rateTreatment outcomeArticle0003211129000052-s2.0-8487979601353554015723143955https://doi.org/10.1007/s12094-012-0960-6OncologySmall Cell Lung Carcinoma; Amrubicin; EtoposideCarboplatinCisplatinCyclophosphamideDoxorubicinEtoposideIrinotecanPlatinum complexTopotecanVincristineAdultAgedArticleCancer chemotherapyCancer prognosisEastern cooperative oncology group performance statusFemaleHumanLung small cell cancerMajor clinical studyMaleOverall survivalProgression free survivalRetrospective studyScoring systemSurvival timeTurkey (republic)1699-3055